Advancements in Cell Therapies and Sickle Cell Disease

Orca Bio presents promising data at the 65th ASH Annual Meeting for its investigational high-precision cell therapies, Orca-T and Orca-Q, showcasing potential to expand treatment to additional patient groups. FDA approvals for gene therapies for sickle cell disease at ASH, with companies like Vertex Pharmaceuticals and Bluebird bio presenting updated data. A study suggests CAR-T cell therapy effective in treating autoimmune diseases. Additionally, a social media analysis highlights ongoing challenges in caring for people with sickle cell disease.